Status:
TERMINATED
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
Lead Sponsor:
Vanderbilt University
Conditions:
Platelet Aggregation
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
Aspirin has shown to be beneficial to some patients with certain diseases such as coronary artery disease or stroke. We are investigating how aspirin works on regulating platelets and thromboxane over...
Detailed Description
he purpose of the study is to better understand the mechanism for failure of daily aspirin administration to prevent cardiovascular events in some at risk individuals. We seek to describe the effect o...
Eligibility Criteria
Inclusion
- Males
- Age 18-40 years
- Non-smokers
Exclusion
- ASA/NSAID use previous 14 days.
- Evidence of ASA/NSAID use within previous 14 days at baseline visit based on investigator interpretation of platelet aggregation and platelet secretion studies.
- History of chronic NSAID use.
- Currently taking NSAIDs, corticosteroids, or anticoagulants.
- History of coronary artery disease, myocardial infarction, coronary artery bypass grafting, percutaneous angioplasty, diabetes mellitus or stroke.
- History of gastric,duodenal, or esophageal ulcers or serious gastrointestinal bleed.
- History of frequent headaches, pain syndrome, or other condition requiring frequent use of analgesics.
- History of adverse reaction to ASA.
- Initial platelet count \<100K/µl or \>500K/µl.
- Initial hematocrit \<35% or \>50%.
- Weight less than 110 pounds.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00748371
Start Date
June 1 2004
End Date
February 1 2011
Last Update
April 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University
Nashville, Tennessee, United States, 37232-6602